VRTX — VERTEX PHARMACEUTICALS INC / MA
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 875320 ·
Last close
$526.19
Market Cap
$133.37B
52W High
$560.25
52W Low
$379.72
ADV30
1,043,280
Next earnings
2026-11-02
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 3,333,900,000 | 2,844,700,000 | 1,268,700,000 | 1,099,800,000 | 27,423,300,000 | 6,143,500,000 | 7,175,400,000 |
| Mar 2026 | 2,986,900,000 | 2,594,100,000 | 1,138,800,000 | 1,031,400,000 | 26,484,400,000 | 5,492,900,000 | 7,122,500,000 |
| Dec 2025 | 3,190,000,000 | 2,724,000,000 | 1,130,300,000 | 1,191,100,000 | 25,643,000,000 | 5,084,800,000 | 6,977,200,000 |
| Sep 2025 | 3,076,400,000 | 2,661,600,000 | 1,238,800,000 | 1,082,900,000 | 24,862,300,000 | 4,939,600,000 | 7,543,500,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$4,292,900,000
Investing CF
$-882,800,000
Financing CF
$-2,197,200,000
CapEx
$-496,800,000
Dividends Paid
—
Buybacks
$-2,332,200,000
EPS Diluted TTM
$17.18
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$15,691,200,000
Inventory
$1,765,100,000
Receivables
$2,134,300,000
ST Investments
$1,708,900,000
EBIT TTM
$5,043,900,000
Pretax Income TTM
$5,274,500,000
Interest Exp TTM
$13,300,000
Analysts
25
Yahoo Snapshot (yfinance, live)
Total Revenue
$12,587,200,512
EBITDA
$5,100,499,968
Free Cash Flow
$2,627,887,616
Enterprise Value
$124,769,099,776
Total Cash
$7,852,400,128
Total Debt
$1,977,600,000
Shares Out
253,460,924
Trailing EPS
$17.16
Book Value
$79.92
ROE
23.5%
ROA
11.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 12,001,300,000 | 4,554,400,000 | 3,953,200,000 | 25,643,000,000 | 6,977,200,000 | 18,665,800,000 | 3,631,400,000 |
| Dec 2024 | 11,020,100,000 | -233,400,000 | -535,600,000 | 22,533,200,000 | 6,123,600,000 | 16,409,600,000 | -492,600,000 |
| Dec 2023 | 9,869,200,000 | 3,780,400,000 | 3,619,600,000 | 22,730,200,000 | 5,149,800,000 | 17,580,400,000 | 3,537,300,000 |
| Dec 2022 | 8,930,700,000 | 4,249,900,000 | 3,322,000,000 | 18,150,900,000 | 4,238,200,000 | 13,912,700,000 | 4,129,900,000 |
TTM Snapshot
Revenues TTM
$10,359,900,000
NetIncome TTM
$3,657,500,000
OpCashFlow TTM
$0
Assets (Latest)
$25,643,000,000
Forward EPS
$20.13
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NVO | NOVO NORDISK A S | $129.75B | $38.80 | — |
| BMY | BRISTOL MYERS SQUIBB CO | $128.41B | $62.86 | — |
| PFE | PFIZER INC | $163.41B | $28.67 | — |
| ABT | ABBOTT LABORATORIES | $175.27B | $101.29 | — |
| GSK | GSK plc | $98.62B | $49.24 | — |
News headlines (Yahoo Finance, 1h cache)
2 Healthcare Stocks That Just Delivered Great News for Investors
2026-09-26 20:21 · Yahoo
Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know
2026-09-24 20:50 · Yahoo
Will Vertex's Kidney Disease Pipeline Be a New Growth Engine?
2026-09-24 14:27 · Yahoo
CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
2026-09-24 13:02 · Yahoo
Vertex (VRTX) Stock Could Be 24% Undervalued As Kidney Trial Progress Continues
2026-09-24 03:23 · Yahoo
Vertex Posts Positive Phase II Data on Kidney Disease Drug
2026-09-23 16:08 · Yahoo
The Surprise That Sent Vertex — And Its Chief Rival — Soaring
2026-09-22 20:17 · Yahoo
Twin Moves: VRTX Rises On Kidney Disease Trial Results, MAZE Rallies Harder
2026-09-22 17:01 · Yahoo
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
2026-09-22 13:00 · Yahoo
Maze Therapeutics (MAZE) Shares Moved, So What Is Driving Attention Now?
2026-09-25 04:23 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.